Halozyme and Incyte sign licence agreement for INCA033989 formulations

Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.

The post Halozyme and Incyte sign licence agreement for INCA033989 formulations appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.